A Marsh survey indicates that GLP-1 drugs, AI billing, and disputes related to the No Surprises Act are each contributing an additional full percentage point to the trend.
Marsh survey finds GLP-1 drugs, AI billing, and No Surprises Act disputes are each adding a full percentage point to trend